Skip to main content

Table 3 Secondary parameters of piperaquine pharmacokinetics in pregnant and non-pregnant women with uncomplicated P . falciparum malaria

From: A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan

Secondary parameters Total Non-pregnant women Pregnant women p-value
CMAX (ng/mL) 158 [40.6-363] 102 [40.6-235] 185 [109–363] 0.021
TMAX (hours) 2.62 [0.887-4.64] 1.48 [0.887-4.18] 3.07 [1.65-4.64] 0.018
Half-life (days) 23.4 [19.1-33.3] 25.7 [20.9-33.3] 22.1 [19.1-25.8] 0.001
Day 7 concentration (ng/mL) 58.3 [16.6-146] 55.4 [16.6-146] 60.7 [40.1-103] 0.671
Day 28 concentration (ng/mL) 15.9 [4.85-38.6] 15.4 [4.85-38.6] 16.1 [9.68-26.8] 0.840
AUC0->90 (ng*h/mL) 40600 [12400–100000] 38000 [12400–100000] 42700 [27100–68700] 0.799
AUC48h->90 (ng*h/mL) 36400 [10600–90300] 35300 [10600–90300] 37700 [23500–63200] 0.887
  1. Secondary parameters are predicted using the final model and values are presented as median [range]. The p-values are calculated with a Mann–Whitney U-test.
  2. CMAX is the predicted maximum concentration after the first dose and TMAX is the time to CMAX. Half-life is the estimated terminal elimination half-life. Day 7 and 28 concentrations are the model predicted plasma concentrations of piperaquine at day 7 and 28, respectively. AUC0->90 is the predicted area under the concentration-time curve from time zero extrapolated to day 90. AUC48h->90 is the predicted area under the concentration-time curve from 48 hours extrapolated to day 90.